Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 2, 2010, Pages 76-80

  Zakeri Milani, Parvin ^a,b   Valizadeh, Hadi ^a,c   Islambulchilar, Ziba ^a,d   Nemati, Mahboob ^a,e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiotensin II receptor antagonist; Antihypertensive; CAS 137862 53 4; Valsartan, bioavailability, bioequivalence

Indexed keywords

VALSARTAN;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TABLET FORMULATION; VOLUNTEER;

EID: 77249095166     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296252     Document Type: Article

References (23)

1. Li H, Wang Y, Jiang Y, Tang Y, Wang J, Zhao L, et al. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852(1-2):436-42.
2. Remuzzi A, Perico N, Remuzzi G. Pharmacological and clinical profile of valsartan. Drugs Today (Barc). 1998; 34(11):973-986.
3. Nie J, Zhang M, Fan Y, Wen Y, Xiang B, Feng YQ. Biocompatible in-tube solid-phase microextraction coupled to HPLC for the determination of angiotensin II receptor antagonists in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;828(1-2):62-9.
4. 1 blockers, ARBs, Sartans): similarities and differences. Netherlands Heart J. 2006;14(11):381-7.
5. Yan J, Wang W, Chen L, Chen S. Electrochemical behavior of valsartan and its determination in capsules. Colloids Surf B Biointerfaces. 2008;67(2):205-9.
6. Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, et al. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007;43(5):1769-74.
7. Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222-8.
8. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1:S73-86.
9. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52(2):115-20.
10. Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Bühlmayer P, et al. Pharmacokinetic, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997;27(1):59-71.
11. Sweetman S. Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2007.
12. Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and highperformance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;832(1):169-72.
13. Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal. 2005;39(3-4):624-30.
14. Valizadeh H, Zakeri-Milani P, Islambulchilar Z, Tajerzadeh H. A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies. J AOAC Int. 2006;89(1):88-93.
15. Nemati M, Valizadeh H, Ansarin M, Ghaderi F. Development of a simple and sensitive high-performance liquid chromatography method for determination of glucosamine in pharmaceutical formulations. J AOAC Int. 2007;90(2): 354-7.
16. Miller JC, Miller, JN. Statistics for Analytical Chemistery. Chichester (UK): Ellis Horwood Ltd; 1993.
17. FDA. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products; General considerations. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2003 [cited 2009 May 16]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ ucm070124.pdf
18. Zakeri-Milani P, Valizadeh H. Comparative bioavailability study of two olanzapine formulations administered orally in healthy male volunteers. Pharm World Sci. 2008;30(5): 702-3.
19. Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008;58(2):97-100.
20. Valizadeh H, Barghi L, Jalilian H, Islambulchilar Z, Zakeri-Milani P. Bioequivalence of fexofenadine tablet formulations assessed in healthy Iranian volunteers. Arzneimittelforschung. 2009;59(7);345-9.
21. Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S, Nemati M. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneimittelforschung. 2009;59(8);429-32.
22. Asiri YA, Al-Said MS, Al-Khamis KI, Niazy EM, El-Sayed YM, Al-Rashood KA, et al. Comparative bioavailability study of cefixime (equivalent to 100 mg/5 ml) suspension (Winex vs. Suprax) in healthy male volunteers. Int J Clin Pharmacol Ther. 2005;43(10):499-504.
23. Schall R, Luus HG. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol. 1992;30(5):153-9.